Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Peptide-based immunization therapy for treatment of atherosclerosis

A technology for atherosclerosis and mammals, applied in the direction of anti-animal/human immunoglobulin, chemical instruments and methods, peptides, etc., can solve problems such as adverse immune reactions

Inactive Publication Date: 2015-07-22
CARDIOVAX
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, a problem with this approach is that it is still not known what structure of oxidized LDL induces a protective immune response, and whether oxidized LDL also contains epitopes that could elicit an adverse immune response

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Peptide-based immunization therapy for treatment of atherosclerosis
  • Peptide-based immunization therapy for treatment of atherosclerosis
  • Peptide-based immunization therapy for treatment of atherosclerosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0033] The molecular characterization of epitopes of oxidized LDL that lead to antibody-dependent immune responses in humans was investigated. The method used takes advantage of the fact that immune responses are almost always directed against peptide sequences with a length of 5 to 6 amino acids. LDL contains only one protein, apolipoprotein B, which is 4563 amino acids in length. During oxidation, apolipoprotein B is cleaved and aldehyde adducts are attached to positively charged amino acids, particularly lysine. This means that immune cells have access to peptide sequences that are not normally exposed to the immune system due to the three-dimensional structure of apolipoprotein B, and / or that normally exposed peptide sequences bind aldehydes to haptenize them, thus possessing immunogenicity.

[0034] Therefore, the following peptides, whether in their native form or as MDA derivatives, should be present in sufficient quantities to generate an immune response are:

[003...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to antibodies raised against fragments of apolipoprotein B, in particular defined peptides thereof, for immunization or therapeutic treatment of mammals, including humans, against ischemic cardiovascular diseases, using one or more of said antibodies.

Description

[0001] The present invention is a divisional application of the Chinese application number: 02808940.5 (PCT / SE02 / 00679); the filing date of the original application is April 5, 2002, and the title of the invention is: peptide-based immunotherapy for the treatment of atherosclerosis therapy, and a peptide-based assay to determine the immune response to oxidized LDL. technical field [0002] The present invention relates to novel peptides, in particular peptides for use in immunotherapy against atherosclerosis and in peptide-based ELISA assays for determining immune responses against oxidized low-density lipoproteins, and Diagnose the presence or absence of atherosclerosis. [0003] In particular, the invention includes: [0004] 1) The use of any of the peptides listed in Table 1 in immunotherapy or "anti-atherosclerosis vaccine", said peptides are used alone or in combination in natural or MDA-modified form, preferably with appropriate carriers and adjuvants Drugs are used s...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K16/18A61K39/395A61K39/00A61P9/10C07K7/08G01N33/53A61KA61K38/00A61K38/17A61K39/385A61K39/39C07K14/775
CPCC07K16/18C07K14/775A61K39/00A61K38/1709A61P37/02A61P7/06A61P9/00A61P9/10
Inventor 扬·尼尔森普里迪曼·K·沙赫
Owner CARDIOVAX
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com